Finance

Lists
ZBIO:NASDAQ
Zenas Biopharma Inc
24,86 USD
-1,19%
(-0,30) 1D
24,86 USD
0,00% (0,00)
After hours
Closed: 14-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
24,82 USD
High
26,49 USD
Low
24,39 USD
Mkt. cap
1,62 млд
Avg. vol.
682,64 миң
Volume
0,00
52-wk high
44,54 USD
52-wk low
13,50 USD
EPS
-8,97 USD
Shares outstanding
65,18 млн
No. of employees
167
Open
24,82 USD
High
26,49 USD
Low
24,39 USD
Mkt. cap
1,62 млд
Avg. vol.
682,64 миң
Volume
0,00
52-wk high
44,54 USD
52-wk low
13,50 USD
EPS
-8,97 USD
Shares outstanding
65,18 млн
No. of employees
167
News stories
From web sources and news partners
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersУолтем, Массачусетс, Америка Кошмо Штаттары
Sector-
Websitezenasbio.com
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current 24,86 USD
55,00 USD (+121,24%)
Average
44,80 USD (+80,21%)
Lowest
32,00 USD (+28,72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Wedbush
Buy
Maintained
45,00 USD
+81%
10/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
44,00 USD
+77%
10/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
48,00 USD
+93,1%
10/12/2026
Martin Fan
Wedbush
Buy
Maintained
45,00 USD
+81%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
32,00 USD
+28,7%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
45,00 USD
+81%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
55,00 USD
+121,2%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
44,00 USD
+77%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
55,00 USD
+121,2%
03/17/2026
Last report
2026-ж., 13-авг.
Fiscal period
Q2 2026
-1,77 USD / -0,75 USD
-134,44%miss
Revenue / Est. (USD)
1,00 млн / 15,00 млн
-93,33%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
1,00 млн
Cost of goods sold
34,40 млн
55,72 млн
60,44 млн
62,91 млн
Cost of revenue
34,40 млн
55,72 млн
60,44 млн
62,91 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,18 млн
15,59 млн
16,91 млн
15,75 млн
Operating expense
13,18 млн
15,59 млн
16,91 млн
15,75 млн
Total operating expenses
47,58 млн
71,31 млн
77,35 млн
78,66 млн
Operating income
-47,58 млн
-71,31 млн
-77,35 млн
-77,66 млн
Other non operating income
1,08 млн
-7,48 млн
-24,00 миң
16,00 миң
EBT including unusual items
-51,50 млн
-240,34 млн
-80,99 млн
-111,34 млн
EBT excluding unusual items
-46,50 млн
-73,66 млн
-80,99 млн
-81,34 млн
Income tax expense
-
106,00 миң
-
114,00 миң
Effective tax rate
-
-0,04%
-
-0,10%
Other operating expenses
-
-
-
-
Net income
-51,50 млн
-240,44 млн
-80,99 млн
-111,46 млн
Net profit margin
-
-
-
-11 145,60%
Earnings per share
-1,22
-1,39
-1,46
-1,77
Interest and investment income
-
12,15 млн
3,02 млн
6,60 млн
Interest expense
-
-7,33 млн
-6,63 млн
-10,30 млн
Net interest expenses
-
4,82 млн
-3,61 млн
-3,70 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,57 млн
-71,30 млн
-77,34 млн
-77,66 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору